

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 February 2005 (24.02.2005)

PCT

(10) International Publication Number
WO 2005/016867 A3

(51) International Patent Classification⁷: **C07C 233/55**,
C07D 209/18, 317/60, 217/14, C07C 237/22, C07D
215/36, C07C 235/38, C07D 333/60, C07C 235/24, A61K
31/196, 31/33

Essex CM19 5AW (GB). SMITH, Ian, Edward, David
[GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage
Hertfordshire SG1 2NY (GB).

(21) International Application Number:
PCT/GB2004/003516

(74) Agent: THORNLEY, Rachel, Mary; GlaxoSmithKline,
Corporate Intellectual Property (CN925.1), 980 Great West
Road, Brentford Middlesex TW8 9GS (GB).

(22) International Filing Date: 13 August 2004 (13.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0319126.9 14 August 2003 (14.08.2003) GB

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, PO Box 7929, Philadelphia,
Pennsylvania 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CAMPBELL,
Mathew [GB/GB]; GlaxoSmithKline, Gunnels Wood
Road, Stevenage Hertfordshire SG1 2NY (GB). HAT-
LEY, Richard, Jonathan [GB/GB]; GlaxoSmithKline,
Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY
(GB). HEER, Jag, Paul [GB/GB]; GlaxoSmithKline,
New Frontiers Science Park South, Third Avenue, Harlow
Essex CM19 5AW (GB). MASON, Andrew, McMurt-
trie [GB/GB]; GlaxoSmithKline, Gunnels Wood Road,
Stevenage Hertfordshire SG1 2NY (GB). PINTO, Ivan,
Leo [GB/GB]; GlaxoSmithKline, Gunnels Wood Road,
Stevenage Hertfordshire SG1 2NY (GB). RAHMAN,
Shahzad, Sharooq [GB/GB]; GlaxoSmithKline, New
Frontiers Science Park South, Third Avenue, Harlow

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report

(88) Date of publication of the international search report:
31 March 2005

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ANTHRANILIC ACID DERIVATIVES AND THEIR USE AS ACTIVATORS OF THE HM74A RECEPTOR



(57) Abstract: Therapeutically active anthranilic acid derivatives of Formula (I) wherein R¹, R² and Z are as defined in the speci-
fication, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compounds and the use
of the compounds in therapy, particularly in the treatment of diseases in which under-activation of the HM74A receptor contributes
to the disease or in which activation of the receptor will be beneficial, are disclosed.